Cargando…

Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report

BACKGROUND: The incidence of gemcitabine-induced hemolytic uremic syndrome has already been described in adults. Several approaches have been employed in the treatment of gemcitabine-induced hemolytic uremic syndrome with different outcomes. One of the most promising agents is eculizumab, which is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Facchini, Ludovica, Lucchesi, Maurizio, Stival, Alessia, Roperto, Rosa Maria, Melosi, Francesca, Materassi, Marco, Farina, Silvia, Tintori, Veronica, de Martino, Maurizio, Sardi, Iacopo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530476/ https://www.ncbi.nlm.nih.gov/pubmed/28747219 http://dx.doi.org/10.1186/s13256-017-1373-5

Ejemplares similares

The use of eculizumab in gemcitabine induced thrombotic microangiopathy
por: Krishnappa, Vinod, et al.
Publicado: (2018)

Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre
por: Grall, Maximilien, et al.
Publicado: (2021)

Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab
por: Efe, Orhan, et al.
Publicado: (2021)

Gemcitabine-induced thrombotic microangiopathy treated with eculizumab: a case report
por: Van den Eeckhaut, Lisa, et al.
Publicado: (2022)

Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life‐saving treatment
por: Gosain, Rahul, et al.
Publicado: (2017)

Eculizumab in chemotherapy-induced thrombotic microangiopathy
por: Schulte-Kemna, Lena, et al.
Publicado: (2020)

The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
por: Gabr, Jihad Ben, et al.
Publicado: (2020)

Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab
por: Jin, Anna, et al.
Publicado: (2016)

Scleroderma Renal Crisis With Thrombotic Microangiopathy Treated With Eculizumab
por: Saba, Ludovic, et al.
Publicado: (2022)

Gemcitabine-Induced Renal Thrombotic Microangiopathy
por: Chaudhary, Ankur, et al.
Publicado: (2023)

An infant with hyperalertness, hyperkinesis, and failure to thrive: a rare diencephalic syndrome due to hypothalamic anaplastic astrocytoma
por: Stival, Alessia, et al.
Publicado: (2015)

Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease
por: Chonat, Satheesh, et al.
Publicado: (2020)

Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy
por: Gomez-Ganda, Laura, et al.
Publicado: (2021)

The Use of Anthracyclines for Therapy of CNS Tumors
por: da Ros, Martina, et al.
Publicado: (2015)

Drug-induced Thrombotic Microangiopathy Caused by Gemcitabine
por: Hasan, Askari, et al.
Publicado: (2018)

Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding
por: Fujita, Yoko, et al.
Publicado: (2020)

Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series
por: Vitkauskaitė, Monika, et al.
Publicado: (2022)

Bevacizumab-Associated Thrombotic Microangiopathy Treated with Eculizumab: A Case Report
por: Padilha, Wallace Stwart Carvalho, et al.
Publicado: (2023)

Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
por: Iorio, Anna Lisa, et al.
Publicado: (2016)

The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report
por: Bjørkto, Magnus Holter, et al.
Publicado: (2021)

Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome
por: Thomas, Christie P., et al.
Publicado: (2015)

Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab
por: Uriarte, Maite Hurtado, et al.
Publicado: (2018)

Treatment of Chemotherapy-Induced Thrombotic Microangiopathy with Eculizumab in a Patient with Metastatic Breast Cancer
por: Hausberg, Martin, et al.
Publicado: (2019)

A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy
por: Wright, Rachael D., et al.
Publicado: (2020)

Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma
por: Rassner, Michael, et al.
Publicado: (2021)

Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT
por: Mizuno, Kana, et al.
Publicado: (2022)

A rare case report of gemcitabine-induced thrombotic microangiopathies
por: Madkhali, Mohammed Ali
Publicado: (2021)

Case report: Thrombotic microangiopathy concomitant with macrophage activation syndrome in systemic lupus erythematosus refractory to conventional treatment successfully treated with eculizumab
por: Yamaguchi, Makoto, et al.
Publicado: (2023)

Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
por: Lanfranco, Luca, et al.
Publicado: (2017)

Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab
por: Allinovi, Marco, et al.
Publicado: (2017)

Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy
por: Haninger-Vacariu, Natalja, et al.
Publicado: (2020)

Unique Presentation of Bortezomib-Associated Thrombotic Microangiopathy Responsive to Therapeutic Plasma Exchange and Eculizumab Therapy
por: Sterner, Robert C., et al.
Publicado: (2022)

Complement-Mediated Thrombotic Microangiopathy Associated with Lupus Nephritis Treated with Eculizumab: A Case Report
por: Torres, Everardo Arias, et al.
Publicado: (2021)

Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy
por: Sridharan, Meera, et al.
Publicado: (2022)

Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
por: Acosta-Medina, Aldo A., et al.
Publicado: (2022)

Eculizumab Treatment in a Patient with Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy and Steroid-Refractory Acute Graft Versus Host Disease
por: Fernández, Cristina, et al.
Publicado: (2015)

Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis
por: Zhang, Rui, et al.
Publicado: (2021)

Thrombotic Microangiopathy Secondary to Systemic Sclerosis with Severe Complement Activation Not Responsive to Eculizumab: A Case Report
por: Nakamura, Masahiko, et al.
Publicado: (2022)

Gemcitabine-Induced Thrombotic Microangiopathy Managed Conservatively in a Patient of Breast Cancer
por: Ghumman, Ghulam Mujtaba, et al.
Publicado: (2022)

Improvement of Breast Cancer-Associated Pulmonary Tumor Thrombotic Microangiopathy With Carboplatin and Gemcitabine
por: Tran, Helen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b9ttv6m2sh9kbtmumkvuk7t6ff